Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 951 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| C | OTHER | 40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 of each 21 day cycle until disease progression, study drug intolerability or withdrawal of consent. |
| E | EXPERIMENTAL | 40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (20mg/kg) on days 1-2 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent. |
| B | EXPERIMENTAL | 40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus AMG 951 (rhApo2L/TRAIL) (8mg/kg) for 5 days per 21 days cycle until disease progression, study drug intolerability or withdrawal of consent. |
| A | OTHER | 40 subjects will receive up to 6 cycles of Carboplatin (AUC = 6.0mg/ml.min) and Paclitaxel (200mg/m2) only |
| D | EXPERIMENTAL | 40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (8mg/kg) on days 1-5 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent. |
| Name | Type | Description |
|---|---|---|
| AMG 951 (rhApo2L/TRAIL) | DRUG | AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5). |
| Bevacizumab | DRUG | Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF). |
| Carboplatin | DRUG | Standard platinum based chemotherapy |
| Paclitaxel | DRUG | Standard taxane chemotherapy |
Inclusion Criteria: * Histologically or cytologically confirmed Non-Small Cell Lung Cancer (NSCLC). Mixed tumors will be categorized by the predominant cell type unless small cell elements are present in which case the patient is ineligible. Cytologic or histologic elements can be established on me...
Top 20 of 90 competitors
AMG 951 was studied for the treatment of non-small cell lung cancer (NSCLC). Specifically, it was evaluated in previously untreated patients receiving chemotherapy with or without bevacizumab. AMG 951 is an investigational agent and is not approved for any indication.
AMG 951 is being developed by Amgen Inc. (ticker: AMGN). Amgen sponsored the clinical trial evaluating AMG 951 in non-small cell lung cancer.
AMG 951 is in Phase 2 clinical development. It has completed one Phase 2 trial in non-small cell lung cancer. No Phase 3 trials have been initiated.
AMG 951 has been studied in one completed Phase 2 trial, NCT00508625, titled "A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab." The trial enrolled 213 patients and was randomized and controlled.